Biogen Idec (NASDAQ:[[ticker:BIIB]]) reported a tenth case of a serious brain infection in a patient taking Tysabri, the Cambridge, MA-based company’s drug for multiple sclerosis and Crohn’s disease. The news was disclosed late last Friday on the company’s website (pdf here). Luke wrote back in December about the history of Tysabri, which was pulled from the market in February 2005 after two cases of PML and returned to the market under a strict monitoring program in July 2006.
Author: Roxanne Palmer
Roxanne Palmer is interning at Xconomy's Boston office this summer. She is currently pursuing a master's degree in science and medical Journalism at Boston University after graduating from Brown in 2008 with a degree in English. Her thesis was on Herman Melville's Civil War poetry.
When not chronicling the ups and downs of Boston's tech industry, Roxanne enjoys drawing, swimming, and birdwatching.
Follow her on Twitter at http://twitter.com/roxannedpalmer, or email her at [email protected].
View all posts by Roxanne Palmer
